Desktop version

Home arrow Sociology

  • Increase font
  • Decrease font


<<   CONTENTS   >>

Feverfew

  • Class: anti-inflammatory, anti-histamine, analgesic.
  • Mechanism of action: it’s not yet clear how feverfew works in the prevention of migraine.
  • Use: migraine headache.
  • Dosing: 50 to 150 mg once daily.143
  • Adverse effects: generally well-tolerated.
  • Contraindications: hypersensitivity to feverfew or any of its components.
  • Drug interactions:

° Anticoagulant/antiplatelet drugs: feverfew may inhibit platelet aggregation and may have additional effects and increase the risk of bleeding with these drugs.144 о Cytochrome P4501A2,2CJ9,2C8,2C9,2D6,3A4: feverfew may inhibit CYP 1A2,2C19.14

Cautions: insufficient reliable information for pregnancy and lactation; avoid use.

References

1. Natural Medicines. Natural medicines in the clinical management of fibromyalgia. http://naturaldataba se.therapeuticresearch.com.pitt.idm.oclc.org/ce/CECourse.aspx?cs=naturalstandard&s=ND&pm=5 &pc=17-108 (accessed 27 December 2017).

  • 2. McCarty D.J., Csuka M., McCarthy G., Trotter D. Treatment of pain due to fibromyalgia with topical capsaicin: a pilot study. Semin Arthritis Rheum 1994;23(6):41 —7.
  • 3. Sandoval M., Charbonnet R.M.. Okuhama N.N., et al. Cat’s claw inhibits TNFalpha production and scavenges free radicals: role in cytoprotection. Free Radic Biol Med 2000;29(l):71-8.
  • 4. Piscoya J., Rodriguez Z., Bustamante S.A., et al. Efficacy and safety of freeze-dried cat’s claw in osteoarthritis of the knee: mechanisms of action of the species Uncaria guianensis. Inflamm Res 2001;50(9):442-8.
  • 5. Mur E., Hartig F., Eibl G., Schirmer M. Randomized double blind trial of an extract from the pentacy- clic alkaloid-chemotype of Uncaria tomentosa for the treatment of rheumatoid arthritis. J Rheumatol 2002;29(4):678-81.
  • 6. Chen C.X., Jin R.M., Li Y.K., et al. Inhibitory effect of rhynchophylline on platelet aggregation and thrombosis. Zhongguo Yao LiXueBao 1992; 13(2): 126—30.
  • 7. Zhou J., Zhou S. Antihypertensive and neuroprotective activities of rhynchophylline: the role of rhynchophylline in neurotransmission and ion channel activity. Jethnopharmacol 2010; 132(1):15—27.
  • 8. Budzinski J.W., Foster B.C., Vandenhoek S., Arnason J.T. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7(4):273-82.
  • 9. Muller A.C., Kanfer I. Potential pharmacokinetic interactions between antiretrovirals and medicinal plants used as complementary and African traditional medicines. Biopharm Drug Dispos 2011 ;32(8):458—70.
  • 10. McGuffin M., Flobbs C., Upton R., Goldberg A., eds. American Herbal Products Association’s Botanical Safety Handbook. Boca Raton. FL: CRC Press, LLC, 1997.
  • 11. Chantre P., Cappelaere A., Leblan D., et al. Efficacy and tolerance or Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine 2000;7(3): 177-83.
  • 12. Chrubasik S., Thanner J., Ktinzel O., et al. Comparison of outcome measures during treatment with the proprietary Harpagophytum extract doloteffin in patients with pain in the lower back, knee or hip. Phytomedicine 2002;9(3): 181—94.
  • 13. Chrubasik S., Junck H., Breitschwerdt H., Conradt C., Zappe H. Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomized, placebo-controlled, double- blind study. Eurj Anaesthesiol 1999; 16(2): 118—29.
  • 14. Unger M., Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004; 18(19):2273—81.
  • 15. Romiti N., Tramonti G., Corti A., Chieli E. Effects of devil’s claw (Harpagophytum procumbens) on the multidrug transporter transporter ABCBl/P-glycoprotein. Phytomedicine 2009:16(12): 1095—100.
  • 16. Brinker F. Herb Contraindications and Drug Interactions, 2nd ed. Sandy, OR: Eclectic Medical Publications, 1998.
  • 17. Shaw D., Leon C„ Kolev S., Murray V. Traditional remedies and food supplements: a 5-year toxicological study (1991-1995). Drug So/1997;17(5):342-56.
  • 18. Mahomed I.M., Ojewole J.A.O. Oxytocin-like effect of Harpagophytum procumbens [Pedaliacae] secondary root aqueous extract on rat isolated uterus. AfrJTrad CAM 2006;3(1):82—9.
  • 19. Haghighi M., Khalva A., Toliat T, Jallaei S. Comparing the effects of ginger (Zingiber officinale) extract and ibuprofen on patients with osteoarthritis. Arch Iran Med 2005;8:267-71.
  • 20. Niempoog S., Siriarchavatana P., Kajsongkram T. The efficacy of Plygersic gel for use in the treatment of osteoarthritis of the knee. J Med Assoc Thai 2012;95(Suppl 10):S113—9.
  • 21. Ozgoli G., Goli M., Moattar F. Comparison of effects of ginger, mefenamic acid, and ibuprofen on pain in women with primary dysmenorrhea. J Altern Complement Med 2009; 15(2): 129—32.
  • 22. Maghbooli M., Golipour F., Moghimi Esfandabadi A., Yousefi M. Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine. Phytother Res 2014;28(3):412—5.
  • 23. Grpntved A., Brask T, Kambskard J., Hentzer E. Ginger root against seasickness: a controlled trial on the open sea .Acta Otolaryngol 1988; 105( 1—2):45—9.
  • 24. Srivastava K.C. Effect of onion and ginger consumption on platelet thromboxane production in humans. Prostaglandins Leukot Essent Fatty Acids 1989;35(3): 183—5.
  • 25. Akhani S.P., Vishwakarma S.L., Goyal R.K. Anti-diabetic activity of zingiber officinale in streptozoto- cin-induced type I diabetic rats. J Pharm Pharmacol 2004.56(1): 101-5.
  • 26. Ghayur M.N., Gilani A.H. Ginger lowers blood pressure through blockade of voltage-dependent calcium channels. J Cardiovasc Pharmacol 2005;45(l):74-80.
  • 27. Chiang H.M.. Chao P.D., Hsiu S.L., et al. Ginger significantly decreased the oral bioavailability of cyclosporine in rats. Am J Chin Med 2006:34(5):845—55.
  • 28. Okonta J.M., Uboh M., Obonga W.O. Herb-drug interaction: a case study of effect of ginger on the pharmacokinetic of metronidazole in rabbit. Indian J Pharm Sci (India) 2008;70(230):232.
  • 29. Safayhi H., Mack T., Sabieraj J., et al. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxy- genase. J Pharmacolexpther 1992:261(3): 1143-6.
  • 30. Sengupta K., Alluri K.V., Satish A.R., et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for the treatment of osteoarthritis of the knee. Arthritis Res Ther 2008;10(4):R85.
  • 31. Holtmeier W„ Zeuzem S., Preiss J., et al. Randomized, placebo-controlled, double-blind trial of Bosewellia Serrata in maintaining remission of Crohn’s disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 2011; 17(2):573—82.
  • 32. Frank A., Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A 2006;111 2(1—2):255—62.
  • 33. Mikhaeil B.R., Maatooq G.T., Badria F.A., Amer M.M. Chemistry and immunomodulatory activity of frankincense oil. Z Naturforsch C J Biosci 2003;58(3-4):230-8.
  • 34. Chalasani N.. Vuppalanchi R., Navarro V., et al. Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Ann Intern Med 2012; 156( 12):857—60.
  • 35. Zhang F., Altorki N.K., Mestre J.R., Subbaramaiah K., Dannenberg A.J. Curcumin inhibits cyclooxy- genase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999:20(3)445-51.
  • 36. Madhu K., Chanda K., Saji M.J. Safety and efficacy of curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial. Inflammopharmacology 2013;21(2): 129—36.
  • 37. Sharma R.A., McLelland H.R., Hill K.A., et al. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001:7(7): 1894-900.
  • 38. Shah B.H., Nawaz Z„ Pertani S.A., et al. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochetn Pharmacol 1999;58(7): 1167-72.
  • 39. Arun N., Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Humnutr 2002;57( 1):41—52.
  • 40. Somasundaram S., Edmund N.A., Moore D.T., et al. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 2002;62( 13):3868—75.
  • 41. Price R.J., Scott M.P., Giddings A.M., et al. Effect of butylated hydroxytoluene, curcumin, propyl gallate and thiabendazole on cytochrome P450 forms in cultured human hepatocytes. Xenobiotica 2008;38(6):574-86.
  • 42. Yan Y.D., Kim D.H., Sung J.H., Yong C.S., Choi H.G. Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. Int J Pharm 2010;399(1—2):116—20.
  • 43. Shenouda N.S., Zhou C., Browning J.D., et al. Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutrcancer 2004;49(2):200-8.
  • 44. Neerati P., Devde R., Gangi A.K. Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus. Phytother Res 2014;28( 12): 1796—800.
  • 45. Pavithra B.H., Prakash N., Jayakumar K. Modification of pharmacokinetics of norfloxacin following oral administration of curcumin in rabbits. J Vet Sci 2009;10(4):293-7.
  • 46. Junyaprasert V.B., Soonthornchareonnon N.. Thongpraditchote S., Murakami T., Takano M. Inhibitory effect of thai plant extracts on P-glycoprotein mediated efflux. Phytotherres 2006;20(1):79—81.
  • 47. Kusuhara H., Furuie H., Inano A., et al. Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. Br J Pharmacol 2012;166(6): 1793-803.
  • 48. Nayeri A., Wu S., Adams E., et al. Acute calcineurin inhibitor nephrotoxicity secondary to turmeric intake: a case report. Transplant Proc 2017;49( 1): 198—200.
  • 49. Unsworth J., d’Assis-Fonseca A., Beswick D.T., Blake D.R. Serum salicylate levels in a breast fed infant. Ann Rheum Dis 1987;46(8):638—9.
  • 50. Schmid B., Liidtke R., Selbmann H.K., et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: randomized placebo-controlled, double blind clinical trial. Phytother Res 2001 ;15(4):344—50.
  • 51. Sweeney K.R., Chapron D.J., Brandt J.L., et al. Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Clin Pharmacol Ther 1986;40(5):518-24.
  • 52. Krivoy N., Pavlotzky E., Chrubasik S„ Eisenberg E., Brook G. Effect of salicis cortex extract on human platelet aggregation. Planta Med 2001 ;67(3):209—12.
  • 53. Schmid B., Kotter I., Heide L. Pharmacokinetics of salicin after oral administration of a standardized willow bark extract. Eur J Clin Pharmacol 2001 ;57(5):387—91.
  • 54. Mcllwain H., Silverfield J.C., Cheatum D.E., et al. Intra-articular orgotein in osteoarthritis of the knee: a placebo-controlled efficacy, safety, and dosage comparison. Am J Med 1989;87(3):295—300.
  • 55. Goebel K.M., Storck U., Neurath F. Intrasynovial orgotein therapy in rheumatoid arthritis. Lancet 1981;l(8228):1015-7.
  • 56. Nielsen O.S., Overgaard J., Overgaard M., et al. Orgotein in radiation treatment of bladder cancer. A report on allergic reactions and lack of radioprotective effect. Acta Oncol 1987;26(2):101—4.
  • 57. Jensen N.H. Reduced pain from osteoarthritis in hip joint or knee joint during treatment with calcium ascorbate. A randomized, placebo-controlled cross-over trial in general practice. Ugeskr Laeger 2003; 165(25):2563—6.
  • 58. Kanazi G.E., El-Khatib M.F., Yazbeck-Karam V.G., et al. Effect of vitamin C on morphine use after laparoscopic cholecystectomy: a randomized controlled trial. Can J Anaesth 2012;59(6):538—43.
  • 59. Levine M., Rumsey S.C., Daruwala R., Park J.B., Wang Y. Criteria and recommendations for vitamin C intake. JAMA 1999;281(15):1415-23.
  • 60. Houston J.B., Levy G. Drug biotransformation interactions in man VI: acetaminophen and ascorbic acid. J Pharm Sci 1976:65(8): 1218-21.
  • 61. Labriola D., Livingston R. Possible interactions between dietary antioxidants and chemotherapy. Oncology (Williston Park) 1999;13(7):1003—8.
  • 62. Fairweather-Tait S., Hickson K., McGaw B., Reid M. Orange juice enhances aluminium absorption from antacid preparation. Eur J Clin Nutr 1994;48(1):71—3.
  • 63. Hansten P.D., Horn J.R. Drug Interactions Analysis and Management. Vancouver, WA: Applied Therapeutics Inc., 1997.
  • 64. Back D.J., Breckenridge A.M., Maclver M., et al. Interaction of ethinyloestradiol with ascorbic acid in man. Br Med J (Clin Res Ed) 1981:282(6275): 1516.
  • 65. Dysken M.W., Cumming R.J., Channon R.A., Davis J.M. Drug interaction between ascorbic acid and fluphenazine. JAMA 1979:241:2008.
  • 66. Slain D., Amsden J.R., Khakoo R.A., et al. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. Pharmacotherapy 2005;25(2):165-70.
  • 67. Kuo S.M., Lin C.P., Morehouse H.F. Jr. Dihydropyridine calcium channel blockers inhibit ascorbic acid accumulation in human intestinal Caco-2 cells. Life Sci 2001 ;68(15):1751—60.
  • 68. Feetam C.L., Leach R.H., Meynell M.J. Lack of a clinically important interaction between warfarin and ascorbic acid. Toxicol Appl Pharmacol 1975;31(3):544—7.
  • 69. Edmonds S.E., Winyard P.G., Guo R., et al. Putative analgesic activity of repeated oral doses of vitamin E in the treatment of rheumatoid arthritis. Results of a prospective placebo controlled double blind trial. Ann Rheum Dis 1997:56(11 ):649—55.
  • 70. Anon. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto miocardico. Lancet 1999;354(9177):447-55.
  • 71. Liede K.E., Haukka J.K., Saxen L.M., Heinonen O.P. Increased tendency towards gingival bleeding caused by joint effect of alpha-tocopherol supplementation and acetylsalicylic acid. Ann Med 1998;30(6):542-6.
  • 72. Landes N.. Pfluger P., Kluth D., et al. Vitamin E activates gene expression via the pregnane X receptor. Biochem Pharmacol 2003;65(2):269—73.
  • 73. Steiner M. Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease. Nutr Rev 1999;57(10):306—9.
  • 74. du Souich P, Garda A.G., Verges J., Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med 2009;13(8A):1451-63.
  • 75. Morreale P, Manopulo R., Galati M., et al. Comparison of the anti-inflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996;23(8):1385—91.
  • 76. Rozenfeld V., Crain J.L., Callahan A.K. Possible augmentation of warfarin effect by glucosamine-chon- droitin. Am J Health Syst Pharm 2004:61 (3):306—7.
  • 77. Hoffer L.J., Kaplan L.N., Hamadeh M.J., Grigoriu A.C., Baron M. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism 2001 ;50(7):767—70.
  • 78. Rindone J.P, Hiller D., Collacott E., Nordhaugen N., Arriola G. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000; 172(2):91—4.
  • 79. Bush T.M., Rayburn K.S., Holloway S.W., et al. Adverse interactions between herbal and dietary substances and prescription medications: a clinical survey. Altern Ther Health Med 2007;13(2):30-5.
  • 80. Balkan B., Dunning B.E. Glucosamine inhibits glucokinase in vitro and produces a glucose-specific impairment of in vivo insulin secretion in rats. Diabetes 1994;43(10):1173—9.
  • 81. Yun J., Tomida A., Nagata K., Tsuruo T. Glucose-regulated stresses confer resistance to vp-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol Res 1995;7(12):583—90.
  • 82. Murav’ev I.u.V., Venikova M.S., Pleskovskaia G.N., Riazantseva T.A, Sigidin I.a.A. Effect of dimethyl sulfoxide and dimethyl sulfone on a destructive process in the joints of mice with spontaneous arthritis. Patol Fiziol Eksp Ter 1991;2:37-9.
  • 83. Brien S., Prescott P., Lewith G. Meta-analysis of the related nutritional supplements dimethyl sulfoxide and methylsulfonylmethane in the treatment of osteoarthritis of the knee. Evid Based Complement Alternat Med 2011:2011:528403.
  • 84. Usha P.R., Naidu M.U. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Investig 2004; 24(61:353-63.
  • 85. Domljan Z., Vrhovac B., Diirrigl T., Pucar I. A double-blind trial of ademetionine vs naproxen in activated gonarthrosis. Int J Clin Pharmacol Ther Toxicol 1989;27(7):329—33.
  • 86. Tavoni A., Vitali C., Bombardieri S., Pasero G. Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study. Am J Med 1987;83(5A): 107—10.
  • 87. Jacobsen S„ Danneskiold-Samspe B., Andersen R.B. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol 1991 ;20(4):294—302.
  • 88. Volkmann H„ Nprregaard J., Jacobsen S., et al. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. Scand J Rheumatol 1997;26(3):206-11.
  • 89. Tavoni A., Jeracitano G., Cirigliano G. Evaluation of S-adenosylmethionine in secondary fibromyalgia: a double-blind study. Clin Exp Rheumatol 1998;16( 1): 106—7.
  • 90. Iruela L.M., Minguez L., Merino J., Monedero G. Toxic interaction of S-adenosylmethionine and clomipramine. Am J Psychiatry 1993; 150(3):522.
  • 91. Charlton C.G., Crowell B. Jr. Parkinson's disease-like effects of S-adenosyl-L-methionine: effects of L-dopa. Pharmacol Biochem Behav 1992;43(2):423—31.
  • 92. Sarzi Puttini R, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-l-tryptophan: a 90-day open study. J Int Med Res 1992:20(2): 182-9.
  • 93. Caruso I., Sarzi Puttini P, Cazzola M., Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990;18(3):201—9.
  • 94. Singhal A.B., Caviness V.S., Begleiter A.F., et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002;58( 1): 130—3.
  • 95. Shils M., Olson A., Shike M. Modern Nutrition in Health and Disease, 8th ed. Philadelphia, PA: Lea and Febiger, 1994.
  • 96. Bagis S., Karabiber M., As I., Tamer L., Erdogan C., Atalay A. Is magnesium citrate treatment effective on pain, clinical parameters and functional status in patients with fibromyalgia? Rheumatol Int 2013:33(11:167-72.
  • 97. Crosby N.. Wilcock A., Corcoran R. The safety and efficacy of a single dose (500 mg or 1 g) of intravenous magnesium sulfate in neuropathic pain poorly responsive to strong opioid analgesics in patients with cancer. J Pain Symptom Manag 2000;19( 1):35—9.
  • 98. Albrecht E., Kirkham K.R., Liu S.S., Brull R. The analgesic efficacy and safety of neuraxial magnesium sulphate: a quantitative review. Anaesthesia 2013;68(2):190—202.
  • 99. Gallelli L., Avenoso T., Falcone D., et al. Effects of acetaminophen and ibuprofen in children with migraine receiving preventive treatment with magnesium. Headache 2014;54(2):313—24.
  • 100. L'Hommedieu C.S., Nicholas D., Armes D.A., et al. Potentiation of magnesium sulfate—Induced neuromuscular weakness by gentamicin, tobramycin, and amikacin. J Pediatr 1983;102(4):629-31.
  • 101. Yamasaki M., Funakoshi S., Matsuda S., et al. Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy. EurJ Clin Pharmacol 2014;70(8):921—4.
  • 102. Ravn H.B., Vissinger H., Kristensen S.D., Husted S.E. Magnesium inhibits platelet activity-An in vitro study. Thromb Haemost 1996;76(1):88—93.
  • 103. Dunn C.J., Goa K.L. Risedronate: a review of its pharmacological properties and clinical use in resorp- tive bone disease. Drugs 2001:61(51:685-712.
  • 104. Rodin S.M., Johnson B.F. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet 1988; 15(41:227-44.
  • 105. Yagi T.. Naito T.. Mino Y., Umemura K.. Kawakami J. Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects. Drug Metab Pharmacokinet 2012;27(2):248-54.
  • 106. Ryan M.P. Diuretics and potassium/magnesium depletion. Directions for treatment. Am J Med 1987;82(3A):38—47.
  • 107. Kivisto K.T., Neuvonen P.J. Enhancement of absorption and effect of glipizide by magnesium hydroxide. Clin Pharmacol Ther 1991:49( 1):39—43.
  • 108. Sompolinsky D., Samra Z. Influence of magnesium and manganese on some biological and physical properties of tetracycline. J Bacteriol 1972;110(2):468—76.
  • 109. Greenberg S., Frishman W.H. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990;30(7):596-608.
  • 110. Hernandez-Ojeda J., Cardona-Munoz E.G., Roman-Pintos L.M., et al. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study. J Diabetes Complications 2012;26(4):352—8.
  • 111. Cordero M.D., Alcocer-Gomez E., de Miguel M., et al. Can coenzyme Q10 improve clinical and molecular parameters in fibromyalgia? Antioxid Redox Signal 2013;19(12): 1356—61.
  • 112. Lister R.E. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J hit Med Res 2002;30(2): 195-9.
  • 113. Shoeibi A.. Olfati N.. Soltani Sabi M., et al. Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial. Acta Neurol Belg 2017; 117(1): 103—9.
  • 114. Portakal O., Ozkaya O., Erden Inal M., et al. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 2000;33(4):279—84.
  • 115. Langsjoen P., Willis P., Folkers R., Folkers K.. Treatment of essential hypertension with coenzyme Q10. Mol Aspects Med 1994:15(Suppl 1):S265—72.
  • 116. Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994:344(8933): 1372-3.
  • 117. Brzezinski A. Melatonin in humans. N Engl J Med 1997;336(3):186—95.
  • 118. Citera G., Arias M.A., Maldonado-Cocco J.A., et al. The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol 2000;19( 1):9—13.
  • 119. Teitelbaum J.E., Johnson C., St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Ahern Complement Med 2006:12(9):857—62.
  • 120. Burke E.R. D-Ribose What You Need to Know. Garden City Park, NY: Avery Publishing Group, 1999: 1-43.
  • 121. Wepner F., Scheuer R., Schuetz-Wieser B., et al. Effects of vitamin D on patients with fibromyalgia syndrome: a randomized placebo-controlled trial. Pain 2014;155(2):261—8.
  • 122. Moon J. The role of vitamin D in toxic metal absorption: a review. J Am Coll Nutr 1994; 13(6):559—64.
  • 123. Schwartz J.B. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol 77)tr 2009;85(2): 198-203.
  • 124. McEvoy G.K., Drug A.H.F.S. Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
  • 125. Odes H.S., Fraser G.M., Krugliak P., Lamprecht S.A., Shany S. Effect of cimetidine on hepatic vitamin D metabolism in humans. Digestion 1990;46(2):61—4.
  • 126. Tannirandorn P., Epstein S. Drug-induced bone loss. Osteoporos hit 2000;11(8):637—59.
  • 127. Tatro D.S., ed. Drug Interactions Facts. St. Louis, MO: Facts and Comparisons Inc., 1999.
  • 128. Vidal-Casariego A., Burgos-Pelaez R., Martlnez-Faedo C., et al. Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis. Exp Clin Endocrinol Diabetes 2013:121(4):234—8.
  • 129. Rossini M., Di Munno O., Valentini G., et al. Double-blind, multicenter trial comparing acetyl l-carni- tine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol 2007;25(2):182-8.
  • 130. Leombruni P., Miniotti M., Colonna F., et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clin Exp Rheumatol 2015;33(1 Suppl 88):S82-5.
  • 131. Martinez E., Domingo P., Roca-Cusachs A. Potentiation of acenocoumarol action by L-carnitine. J Intern Med 1993;233(1):94.
  • 132. Rabbani N.. Alam S.S., Riaz S., et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomized, double-blind placebo-controlled pilot study. Diabetologia 2009;52(2):208-12.
  • 133. Devathasan G., Teo W.L., Mylvaganam A. Methylcobalamin in chronic diabetic neuropathy. A doubleblind clinical and electrophysiological study. Clin Trials J 1986;23:130-40.
  • 134. Xu G., Lv Z.W., Feng Y.,Tang W.Z., Xu G.X. A single-center randomized controlled trial of local meth- ylcobalamin injection for subacute herpetic neuralgia. Pain Med 2013;14(6):884—94.
  • 135. Negrao L., Almeida P., Alcino S., et al. Effect of the combination of uridine, folic acid and vitamin B12 on the clinical expression of peripheral neuropathies. Pain Manag 2014;4(3): 191—6.
  • 136. Sedel F., Papeix C., Bellanger A., et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord 2015;4(2): 159—69. doi:10.1016/j.msard.2015.01.005.
  • 137. Koutsikos D., Agroyannis B., Tzanatos-Exarchou H. Biotin for diabetic peripheral neuropathy. Biomed Pharmacother 1990;44( 10):511—4.
  • 138. Rodriguez-Melendez R., Griffin J.B., Zempleni J. Biotin supplementation increases expression of the cytochrome P450 1B1 gene in Jurkat cells, increasing the occurrence of single-stranded DNA breaks. J Nutr 2004; 134(91:2222-8.
  • 139. Rezapour-Firouzi S., Arefhosseini S.R.. Mehdi F., et al. Immunomodulatory and therapeutic effects of hot-natured diet and со-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients. Complement Ther Med 2013;21(5):473—80.
  • 140. Keen H., Payan J.. Allawi J., et al. Treatment of diabetic neuropathy with gamma-linolenic acid: the gamma-linolenic acid multicenter trial group. Diabetes Care 1993;16(1):8—15.
  • 141. Voroneanu L., Nistor I., Dumea R., Apetrii M., Covic A. Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Res 2016;2016:5147468.
  • 142. Fallahzadeh M.K., Dormanesh B., Sagheb M.M., et al. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis 2012;60(6):896—903.
  • 143. Johnson E.S., Kadam N.P, Hylands D.M., Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J (Clin Res Ed) 1985;291(6495):569—73.
  • 144. Awang D.V.C. Prescribing therapeutic feverfew (Tancetum pathrnium (L.) Schultz Bip., syn. Chrysanthemumparthenium (L.) Bernh). Int Med 1998;1(1): 11—3.
 
<<   CONTENTS   >>

Related topics